title: A potent and selective tacrine analog--biomembrane permeation and physicochemical characterization.
abstract: Cholinesterase inhibitors have been used for years in treatment of Alzheimer's disease (AD). Tacrine is the first acetylcholinesterase inhibitor approved for treating AD by the regulatory agencies around the world. Unfortunately, a number of studies have shown tacrine to be associated with some severe side effects, including hepatotoxicity. These adverse effects may be attributed to its poor selectivity for acetylcholinesterase and have thus necessitated the research and development of more selective cholinesterase inhibitors with a greater specificity and higher potency. The heptylene-linked bis-tacrine analog (bis-THA) of Tacrine is a second-generation inhibitor of acetylcholinesterase, which has a potency that is 1000 times more potent than Tacrine in inhibition of the rat brain acetylcholinesterase and 10,000 times more selective for acetylcholinesterase over butyrylcholinesterase. A series of investigations have thus been initiated to characterize the physicochemical properties (e.g., pKa, partition coefficient, and stability) of this bis-THA analog as compared to its parent molecule (Tacrine). For AD treatment, the cholinesterase inhibitors need to be taken daily for long periods of time. Use of controlled-release dosage forms to deliver drugs for chronic administration, by taking advantage of their rate-controlling drug delivery features, has gained increasing popularity in recent years. On the other hand, the nasal route, which has been used to deliver drugs for achieving a direct delivery to the brain (via the olfactory pathway), could offer the benefits of brain targeting to the delivery of Tacrine and bis-THA. To investigate this feasibility, the permeation of Tacrine and bis-THA across the nasal mucosa was evaluated (in comparison with other absorptive mucosae). Studies of their permeation kinetics across the various absorptive mucosae, which were freshly excised from the domestic pig, indicated that the nasal mucosa could present a viable pathway for the systemic delivery of bis-THA. Delipidization studies suggested that the lipophilic components in the absorptive mucosae could play an important role in the permeation of bis-THA. The bis-THA has a pKa of approximately 8 and its partition coefficient showed a sigmoidal pattern with solution pHs. It was found to be relatively stable at acidic pHs but subjected to a base-catalyzed degradation at the alkaline pHs (> or = 8) and at higher temperatures (> or = 50 degrees C).
authors.affiliation: Controlled Drug-Delivery Research Center, Rutgers University, Piscataway, New Jersey, USA.
authors.forename: George A
authors.initials: GA
authors.lastname: Patani
authors.forename: Yuan Ping
authors.initials: YP
authors.lastname: Pang
authors.forename: Yie W
authors.initials: YW
authors.lastname: Chien
mesh_terms: D000818:Animals; D002021:Buffers; D002463:Cell Membrane Permeability / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000166:cytology / Q000378:metabolism; D008297:Male; D009061:Mouth Mucosa / Q000166:cytology / Q000378:metabolism; D012867:Skin / Q000166:cytology / Q000378:metabolism; D012869:Skin Absorption; D012995:Solubility; D034421:Sus scrofa; D013619:Tacrine / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D002021:Buffers; D002800:Cholinesterase Inhibitors; D013619:Tacrine